SAN FRANCISCO, CALIFORNIA--(Marketwired - Dec. 23, 2013) -
NOT FOR DISTRIBUTION IN THE UNITED STATES WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
Patient Home Monitoring Corp. ("PHM" or the "Company") (TSX VENTURE:PHM) has announced that it has completed a brokered private placement with gross proceeds of $5,750,000 to be used to close acquisitions from its growing pipeline of potential target companies and for additional working capital and general corporate purposes.
PHM earlier announced that it engaged Beacon Securities Limited ("Beacon") to complete a best efforts private placement offering of approximately $5,000,000 (the "Offering"). Beacon was also offered the option to place up to another $750,000. Beacon exercised its entire option, and placed $5,750,000. This Offering positions PHM to continue to pursue attractive healthcare acquisitions. PHM seeks to continue to make acquisitions in the large and fragmented market of small, profitable businesses providing healthcare products and services to chronically ill patients and for working capital and general corporate purposes.
The Offering was completed by issuing 25,000,000 units ("Units") at $0.23 per unit, for gross proceeds to PHM of $5,750,000, each unit consisting of one common share in the capital of PHM and one common share purchase warrant, each whole warrant entitling the holder thereof to acquire one additional common share in the capital of PHM at a price of $0.36 per share for a period of 24 months, subject to certain acceleration provisions in the event that the 20-day volume weighted average trading price of PHM's common shares on the TSX Venture Exchange (the "Exchange") exceeds $0.42.
In connection with the Offering, PHM paid cash commissions of $402,500, and issued broker warrants to purchase 1,750,000 shares of PHM at $0.23 for a period of twenty-four months following the closing date of the Offering.
The Offering closed on December 23, 2013, subject to final approval of the Exchange. All securities issued in connection with the Offering will be subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable securities legislation.
"We are again grateful for support we have received from the capital markets as the Company continues to accelerate profit growth." Michael Dalsin, Chairman of PHM, said. "We will work hard to put the funds to good use for our investors. We also want to thank Beacon for their work supporting PHM."
The securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "1933 Act"), or under any state securities laws, and may not be offered or sold, directly or indirectly, or delivered within the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the 1933 Act) absent registration or an applicable exemption from the registration requirements. This news release does not constitute an offer to sell or a solicitation to buy such securities in the United States.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
The explosive growth in the number of elderly patients in the US healthcare market is creating pressure to provide more efficient delivery systems. Healthcare providers, such as hospitals, physicians and pharmacies, are seeking partners that can offer a range of products and services that improve outcomes, reduce hospital readmissions, and help control costs. PHM fills this need by delivering a growing number of specialized products and services to achieve these goals.
PHM is currently a positive cash flow and profitable company servicing patients with chronic heart disease and will act as a platform for acquisitions. PHM is focused on a highly fragmented and developing market of small privately-held companies servicing chronically ill patients with multiple disease states caused mainly by age and obesity. Because of the new and highly fragmented nature of the market, PHM is actively working to identify and evaluate profitable, annuity-based companies to acquire their patient databases and technical expertise at favorable prices. PHM's post acquisition organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient's services and making life easier for the patient. The expected result is growing EPS with each acquisition and growing revenue and profits from the cross selling efforts.
Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of PHM and anticipated events or results, are assumptions based on beliefs of PHM's senior management as well as information currently available to it. While these assumptions were considered reasonable by PHM at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue operations, decline of reimbursement rates, dependence on few payors, possible new drug discoveries, a novel business model, dependence on key suppliers, granting of permits and licenses in a highly regulated business, competition, low profit market segments as well as general economic, market and business conditions, and could differ materially from what is currently expected.